Updated on 10 October 2015
Market analysis company, BMI Research, reflects that developed countries need to build strategies to maintain the attractiveness of their countries as destinations for clinical trials, especially as the cost of conducting clinical research is forecast to rise.
The research firm indicates that though US and Western Europe are the leading destinations in terms of trial numbers, there is a shift towards conducting trials in Central and Eastern Europe, Latin America and Asia Pacific.
The shift towards Asia is marked by its high population size, low clinical trial cost and policies to attract CROs. BMI expects a continuing shift in clinical trials moving towards other regions particularly in the case for Phase III trials, as early-stage research is likely to remain in developed states.
Multinational pharmaceutical and clinical research organizations have been active in investing in Asia, opening their local operations in different regions and collaborating with regional CROs to get data access.
Given the high number of ongoing clinical trial in China, Pharmaceutical Product Development, (PPD) opened a central laboratory in Shanghai, China, to deliver global scientific and technical laboratory expertise to meet growing client demand for their services in China. The new facility, established in association with Shanghai Clinical Research Center (SCRC), provides analytical equipment to enable high-quality data across a wide range of technologies and applications for all phases of pharmaceutical development. The Shanghai lab adds to PPD's 20 clinical development facilities throughout the Asia-Pacific region, an area of increased focus for the global CRO.